600867 Tonghua Dongbao Pharmaceutical
- 10.43
- +0.06+0.58%
Tonghua Dongbao Pharmaceutical News
Tonghua Dongbao (600867.SH) plans to take a stake in the cutting-edge protein drug innovation company Junhe League to extend its business to the consumer medicine sector
Tonghua Dongbao (600867.SH) announced that the company, as a Series B investor, passed a capital increase of 100 million yuan with its own capital...
Tonghua Dongbao (600867.SH): Plans to subscribe 100 million yuan for Junhe League's additional registered capital of 9.5031 million yuan
Gelonghui, May 7 | Tonghua Dongbao (600867.SH) announced that the company signed the “Capital Increase Agreement for Junhe Biopharmaceuticals (Hangzhou) Co., Ltd.” with Junhe League shareholders such as Dongbao Group, Shanghai Zigang, and Shanghai Songyuan. As a Series B investor, the company subscribed to Junhe League's additional registered capital of RMB 9.5031 million with RMB 9.5031 million. The remaining portion was included in the capital reserve to obtain 8.6759% of Junhe Union's shares on a fully diluted basis after the capital increase was completed. Junhe League is an innovative company in cutting-edge protein drugs, in neurotherapy, skin anti-aging, and subcutaneous fillers
Dongbao Pharmaceutical's Profit, Operating Income Slip in Q1 2024
Tonghua Dongbao Pharmaceutical (SHA:600867) booked a net profit attributable to shareholders of 214.7 million yuan in the first quarter of the year, slipping 14.3% from 250.4 million yuan a year earli
Tonghua Dongbao (600867.SH) announced first-quarter results, net profit of 215 million yuan, a year-on-year decrease of 14.28%
Tonghua Dongbao (600867.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 5.9 during the reporting period...
Guojin Securities: Continued increase in domestic insulin share is expected to drive continued growth in performance
Since May 2022, national special insulin collection has been launched in various provinces and cities. While the price of insulin products has declined, the domestic substitution process has greatly accelerated.
Tonghua Dongbao (600867.SH): GLP-1/GIP dual-target receptor agonist (THDBH120 for injection) has been clinically approved for weight loss indications
Gelonghui, April 24, Tonghua Dongbao (600867.SH) announced that Dongbao Zixing (Hangzhou) Biomedical Co., Ltd. (“Dongbao Zixing”), a wholly-owned subsidiary of the company, recently obtained a clinical trial approval notice from the Drug Evaluation Center (CDE) of the China Drug Administration for injectable THDBH120 weight loss indications. Injectable THDBH120 is a glucagon-like peptide-1 (GLP-1) receptor and glucose-insulin-stimulating polypeptide (GIP) receptor dual-target agonist. It integrates the two insulin-promoting effects of GLP-1 and GIP into more than one
Tonghua Dongbao (600867.SH): Participates in the national centralized drug procurement (insulin special continuation) to be selected
Gelonghui, April 23 | Tonghua Dongbao (600867.SH) announced that on April 23, 2024, the company participated in the national centralized drug procurement (insulin special continuation) declaration process organized by the State Organization's Centralized Drug Procurement and Use Joint Procurement Office (referred to as the “Joint Procurement Office”). Company human insulin injection, sperm protein human insulin injection, argentine human insulin mixed injection (30R), sperm protein human insulin mixed injection (40R), sperm protein human insulin mixed injection (50R), glargine insulin injection, menthong insulin injection, menthong insulin 3
Is Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Latest Stock Performance A Reflection Of Its Financial Health?
Tonghua Dongbao Pharmaceutical's (SHSE:600867) stock is up by a considerable 10% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is th
Tonghua Dongbao Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
A week ago, Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) came out with a strong set of annual numbers that could potentially lead to a re-rate of the stock. Results were good overall, w
Tonghua Dongbao (600867.SH): Net profit in 2023 fell 26.17% year-on-year, and plans to distribute 2.5 yuan for 10 shares
Gelonghui, March 28 | Tonghua Dongbao (600867.SH) released its 2023 annual report. Operating revenue was 3,075 billion yuan, up 10.69% year on year, net profit was 1,168 billion yuan, down 26.17% year on year, after deducting non-net profit of 1,168 billion yuan, up 38.88% year on year, with basic earnings of 0.59 yuan per share. A cash dividend of 2.5 yuan is distributed to all shareholders for every 10 shares.
Tonghua Dongbao (600867.SH): In terms of GLP-1RA, the company cooperated with Kexon Pharmaceuticals to develop overseas markets for liraglutide injections
Gelonghui, March 7 | Tonghua Dongbao (600867.SH) said on an interactive platform that in recent years, the company has been steadily advancing its internationalization strategy, continuously expanding the overseas layout of its products and speeding up the overseas market process. In terms of insulin, in the first half of 2023, the company's application for permission to market insulin injections was officially accepted by the European Medicines Agency. In the second half of 2023, the company reached a strategic cooperation with Jianyou Co., Ltd. to jointly enter the US insulin market. The company is steadily promoting overseas registration of insulin analogues. Insulin glargine has prepared registration data and applications in several developing countries, and completed the process at the same time
Tonghua Dongbao Pharmaceutical (SHSE:600867) Seems To Use Debt Rather Sparingly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might
Tonghua Dongbao (600867.SH): Actively exploring the application of AI technology in drug development and related operations
Gelonghui, Feb. 22丨Tonghua Dongbao (600867.SH) said on the interactive platform that the company continues to pay attention to the development and application of artificial intelligence technology in related fields, and actively explores the application of AI technology in drug development and related operations to continuously improve R&D and operation efficiency.
Guohai Securities: Domestic replacement+opening up the European and American markets, domestic insulin has entered a new stage
The Zhitong Finance App learned that Guohai Securities released a research report saying that with the steady increase in domestic insulin penetration rates and the gradual expansion of overseas markets, leading companies have fully benefited from the growth of the industry. Covered for the first time, giving the insulin industry a “recommended” rating. Focus on the company: Ganli Pharmaceutical (603087.SH) is a leading domestic third-generation insulin, and overseas expansion is imminent; Tonghua Dongbao (600867.SH) is a second-generation insulin leader, accelerating the development of the third-generation insulin market. ▍ Guohai Securities's main opinion is as follows: There are many diabetics in China, and foreign investment accounts for most of the market share. Released according to IDF
Tonghua Dongbao (600867.SH): Summary report on completion of phase I clinical trial of a gout dual-target inhibitor
Gelonghui, Feb. 22丨Tonghua Dongbao (600867.SH) announced that the wholly-owned subsidiary Dongbao Zixing (Hangzhou) Biomedical Co., Ltd. received a clinical trial approval notice for gout dual-target XO/URAT1 inhibitors (THDBH151 tablets) from the State Drug Administration, and has completed a key phase I clinical trial and obtained a clinical trial summary report. The research results showed that the main end goal was reached. After THDBH151 tablets were approved for drug clinical trials by the State Drug Administration, according to the relevant guidelines for innovative domestic chemical drugs, the applicant has
Tonghua Dongbao (600867.SH): GLP-1/GIP dual-target receptor agonist (THDBH120 for injection) weight loss application was accepted for clinical use
Tonghua Dongbao (600867.SH) announced that Dongbao Zixing (Hangzhou) Biomedical Co., Ltd., a wholly-owned subsidiary of the company...
Results: Tonghua Dongbao Pharmaceutical Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Last week, you might have seen that Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) released its full-year result to the market. The early response was not positive, with shares down 2.8% to CN
Tonghua Dongbao (600867.SH): Net profit decreased 25.51% year-on-year in 2023
Gelonghui, January 29丨Tonghua Dongbao (600867.SH) announced the 2023 annual results report. During the reporting period, the company achieved operating income of 309,49,128 million yuan, an increase of 11.39%; operating profit of 136.2527 million yuan, a decrease of 25.30%; total profit of 136.729 million yuan, a decrease of 25.27%; realized net profit attributable to shareholders of listed companies of 1178.3079 million yuan, a year-on-year decrease of 25.51%; achieved net deduction of non-recurring profit and loss attributable to shareholders of listed companies Profit 117,337.
Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Last Week's 4.6% Decline Must Have Disappointed Retail Investors Who Have a Significant Stake
Key Insights Tonghua Dongbao Pharmaceutical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 25 investors hav
Dongbao Pharma Unit's Gout Drug Clinical Study Achieves Primary Endpoint
A study of Dongbao Purple Star (Hangzhou) Biopharmaceutical, a unit of Tonghua Dongbao Pharmaceutical (SHA:600867), showed positive results of the THDBH 130 tablets after the Phase IIa clinical trial
Analysis
Price Target
No Data
